GlassScriptPhysician profile
Anthony S Greer
NPI 1619960465
$5,052.96
in general payments reported to CMS, 2019-2025
37 companies · $829 in 2025
The $829 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $386 · 2021: $507 · 2022: $936 · 2023: $916 · 2024: $812 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $833.99 | 2021-2025 | |
| Corium, LLC | $491.01 | 2022-2025 | Azstarys |
| Tris Pharma INC | $357.49 | 2019-2025 | Dyanavel Xr |
| Neos Therapeutics, LP | $287.17 | 2019-2024 | Adzenys Xr-Odt |
| Lilly USA, LLC | $264.96 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Inspire Medical Systems, INC. | $250.45 | 2023-2025 | Inspire |
| Pfizer INC. | $236.87 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $232.73 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $215.85 | 2022-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $199.35 | 2021-2024 | Qelbree, Qelbree |
| Biohaven Pharmaceutical Holding Company LTD. | $173.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $144.70 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $144.58 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Adlon Therapeutics L.P. | $121.64 | 2019-2021 | |
| Hoffmann-La Roche Limited | $111.78 | 2019 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Greer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.